

Table 1. Descriptive Statistics for anti-glycan antibody levels in RRMS and control groups^a . A more detailed version of table 3 in Schwarz et. Al including segmentation to patients in relapse vs patients in remission.

Sugar Ligand	Signal	Total RRMS (n=107)	MS patients in relapse (n=66)	MS patients in remission (n=41)	PPMS (n= 16)	OAD (n= 27)	OND (n = 50)
Glc(α1,4)Glc(α)	Median, RFU*10 ⁶	10.59	11.96	9.90	8.23	6.47	1.14
	SD	8.76	9.60	8.12	6.41	6.05	6.56
	# p-value (vs RRMS)						
	* p-value (vs Relapsing MS)			0.14*	0.25 [#]	0.06 [#]	<0.001 [#]
α-Glc	Median, RFU*10 ⁶	8.91	11.13	8.47	6.53	6.65	2.07
	SD	9.88	10.90	9.08	13.40	6.28	5.62
	# p-value (vs RRMS)						
	* p-value (vs Relapsing MS)			0.13*	1 [#]	0.36 [#]	<0.001 [#]
α-Rha	Median, RFU*10 ⁶	22.55	20.44	23.36	33.05	18.69	10.15
	SD	15.57	13.70	16.59	18.38	12.84	9.08
	# p-value (vs RRMS)						
	* p-value (vs Relapsing MS)			0.27*	0.3 [#]	0.41 [#]	<0.001 [#]
α-GlcNAc	Median, RFU*10 ⁶	17.38	17.74	16.63	13.72	12.65	4.12
	SD	10.03	8.85	10.76	9.61	8.40	8.52

	# p-value (vs RRMS)							
	* p-value (vs Relapsing MS)							
				0.78*	0.8#	0.07#	<0.001#	

^aMS, multiple sclerosis; OAD, other autoimmune diseases; OND, other neurological diseases; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.